New hope for blistering skin diseases: drug targets harmful antibodies to heal wounds
Disease control
Not yet recruiting
This study tests whether a drug called efgartigimod can lower harmful antibodies that attack the skin in two rare blistering diseases: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA). About 18 participants aged 12 and older will receive…
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated May 09, 2026 05:19 UTC